New England Journal of Medicine· 2015Q1
Metastatik Hormon-Hassas Prostat Kanserinde Kemohormonal Tedavi
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- 2.858atıf
- Q1SCImago
- 2015yıl
Kısa özet
Metastatik hormon-hassas prostat kanseri için androjen yoksunluk tedavisine (AYT) dosetaksel eklenmesi, ortalama sağkalımı 13.6 ay (57.6'ya karşılık 44.0 ay) önemli ölçüde artırdı.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- AYT artı dosetaksel ile ortalama genel sağkalım 57.6 ay iken, sadece AYT ile 44.0 aydı (ölüm için tehlike oranı 0.61, P<0.001).
- İlerleme zamanı ortalaması, kombinasyon tedavisi ile 20.2 ay, sadece AYT ile 11.7 aydı (tehlike oranı 0.61, P<0.001).
- 12. ayda PSA seviyesinin 0.2 ng/mL'nin altında olması, kombinasyon grubunda hastaların %27.7'sinde, sadece AYT grubunda ise %16.8'inde görüldü (P<0.001).
- Kombinasyon tedavisi alan hastalarda grade 3/4 ateşli nötropeni %6.2 oranında görüldü.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
BACKGROUND: Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone. METHODS: We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT alone. The primary objective was to test the hypothesis that the median overall survival would be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among patients receiving ADT alone. RESULTS: A total of 790 patients (median age, 63 years) underwent randomization. After a median follow-up of 28.9 months, the median overall survival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 95% confidence interval [CI], 0.47 to 0.80; P<0.001). The median time to biochemical, symptomatic, or radiographic progression was 20.2 months in the combination group, as compared with 11.7 months in the ADT-alone group (hazard ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). The rate of a prostate-specific antigen level of less than 0.2 ng per milliliter at 12 months was 27.7% in the combination group versus 16.8% in the ADT-alone group (P<0.001). In the combination group, the rate of grade 3 or 4 febrile neutropenia was 6.2%, the rate of grade 3 or 4 infection with neutropenia was 2.3%, and the rate of grade 3 sensory neuropathy and of grade 3 motor neuropathy was 0.5%. CONCLUSIONS: Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.).
Yazarların özeti; kaynağından alınmıştır. New England Journal of Medicine, 2015 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Göğüs ve Solunum Tıbbı
Pulmonary and Respiratory MedicineMedicine